The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes

CONCLUSION: HER2-low accounted for 70% of the cases and correlated with favorable biological markers. The HER2-low group had a significantly better OS than the HER2-0 group. However, the response to NAC was low in the HER2-low group, and this group had the poorest prognosis among all the non-pCR cases. These findings indicate that HER2-low may have a different biology and prognosis and therefore should be classified as a new entity.PMID:38472058 | DOI:10.1016/j.clbc.2024.02.013

Source: Clinical Breast Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Reiki Nishimura Yoshitaka Fujiki Tetsuhiko Taira Toshiko Miyaki Shuichi Kanemitsu Daisuke Yotsumoto Megumi Teraoka Junko Kawano Naomi Gondo Reiko Mitsueda Shinichi Baba Yasuyo Ohi Yoshiaki Rai Yoshiaki Sagara Yasuaki Sagara Source Type: research